Key result
Cerebral embolic protection devices used during transcatheter aortic valve implantation did not reduce overall stroke incidence compared to procedures without the devices.
Why the study?
The efficacy and safety of cerebral embolic protection devices during TAVI remain controversial and require evaluation through randomized controlled trials.
Does the use of cerebral embolic protection devices prevent stroke or mortality in patients undergoing transcatheter aortic valve implantation?
Meta-Analysis (n=11,589)
Open-label
Yes
Does the use of cerebral embolic protection devices prevent stroke or mortality in patients undergoing transcatheter aortic valve implantation?
Answers are grounded in this paper and cite their sources.
Routine use of cerebral embolic protection devices during TAVI does not significantly reduce the incidence of periprocedural stroke or all-cause mortality, though trial sequential analysis suggests current data may still be underpowered to detect modest benefits.
AIMS: Transcatheter aortic valve implantation (TAVI) is associated with procedure-related stroke. Cerebral embolic protection devices (CEPDs) are designed to reduce the risk of embolic debris reaching the brain; however, the evidence supporting their efficacy remains controversial. We aim to evaluate the efficacy and safety of CEPDs in patients undergoing TAVI. METHODS: Major databases were systematically searched up to April 2025. Only randomized controlled trials (RCTs) were included and critically appraised using the Cochrane Risk of Bias (ROB-2) tool. We calculated risk ratios (RRs) with the 95% confidence intervals for the outcomes, and trial sequential analysis (TSA) was conducted to reduce the risk of false-positive results due to random errors. RESULTS: Eight RCTs (11,589 patients) were analyzed. No significant difference was observed in overall stroke incidence between CEPD and control groups (0.92 (95% CI: 0.75-1.14; p = 0.40, I2 = 0%), including disabling and non-disabling strokes. Device-specific analyses showed a non-significant reduction in disabling stroke with the Sentinel device. All-cause mortality, transient ischemic attacks, bleeding, acute kidney injury, delirium, and pacemaker implantation rates were similar between groups. CEPD use was linked to a transient improvement in cognitive function (MoCA scores) at 2-5 days post-TAVI, but this effect was not sustained at later follow-ups. TSA indicated that current evidence is insufficient to definitively refute CEPD efficacy. CONCLUSION: CEPDs show no significant reduction in overall, disabling, or non-disabling stroke, nor in all-cause mortality post-TAVI. TRIAL REGISTRATION: This meta-analysis was registered on PROSPERO. No.: CRD420251026208.
No takes yet. Share an insight, caveat, or question.
Gbreel et al. (2026) conducted a meta-analysis in Severe aortic stenosis undergoing Transcatheter Aortic Valve Implantation (TAVI) (n=11,589). Cerebral embolic protection devices (CEPDs) vs. TAVI without CEPDs was evaluated on Overall stroke incidence (RR 0.92, 95% CI 0.75-1.14, p=0.40). Cerebral embolic protection devices used during transcatheter aortic valve implantation did not reduce overall stroke incidence compared to procedures without the devices.
Synapse has enriched 10 related papers. Consider them for comparative context: